ZMB Member Adalbert Krawczyk
ZMB Member
Adalbert Krawczyk
Next ZMB-Member
Prof. Dr. Adalbert Krawczyk
University Hospital Essen
Hufelandstr. 55
45147 Essen
- +49 201 723 82512
- Website
- Selected Publications
- Publication Metrics
-
- ZMB Research Program
Immunology, Infectious Diseases and Transplantation
Research Overview
- Anti-HSV antibodies
- Nanoparticle based vaccines
- Anti-CMV antibodies
- Coronavirus SARS-CoV-2
- Antiviral Natural Products and Herbal Medicines
- Modification of exosomes for the development of new vaccines
Selected Publications
-
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19In: Nature Communications , Vol. 12 2021, Nr. 1, pp. 1813DOI (Open Access)
-
Acid ceramidase of macrophages traps herpes simplex virus in multivesicular bodies and protects from severe diseaseIn: Nature Communications , Vol. 11 2020, Nr. 1, pp. 1338DOI, Online Full Text (Open Access)
-
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide TherapyIn: Gastroenterology , Vol. 158 2020, Nr. 8, pp. 2180 – 2194DOI (Open Access)
-
Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8⁺ T Cells and Evolve at the Population LevelIn: Gastroenterology , Vol. 156 2019, Nr. 6, pp. 1820 – 1833DOI (Open Access)
-
Understanding HDV and HBsAg kinetics during nucleic acid polymer REP 2139 mono-therapy in HBeAg-negative chronic HBV/HDV co-infected patients via mathematical modelingIn: Journal of Hepatology , Vol. 70 2019, Nr. 1 Suppl., pp. e463
-
Establishment of High Rates of Functional Control and Reversal of Fibrosis Following Treatment of Hbeag Negative Chronic HBV Infection with REP 2139-Mg / REP 2165-Mg, Tenofovir Disoproxil Fumarate and Pegylated Interferon Alpha-2aIn: Hepatology , Vol. 68 2018, Nr. S1, pp. 234A – 235A
-
One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial : REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infectionIn: Journal of Hepatology , Vol. 66 2017, Nr. 1, pp. S96 – S97
-
Update on safety and efficacy in the REP 401 protocol : REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infectionIn: Journal of Hepatology , Vol. 66 2017, Nr. 1, pp. S256 – S257